Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure

References

• Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21(5):365–371.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update. Circulation. 2016;133(4):e38–e360.
   PubMed Web of Science ®Google Scholar
• Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000–2010. Natl Health Stat Report. 2012;108(108):1–8.
   Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update. Circulation. 2010;121(7):e46–e215.
   PubMed Web of Science ®Google Scholar
• Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355–363.
   PubMed Web of Science ®Google Scholar
• Hunt SA. American College of Cardiology, American Heart Association Task Force. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol. 2005;46(6):e1–e82.
   PubMed Web of Science ®Google Scholar
• Jondeau G, Milleron O. Beta-blockers in acute heart failure: do they cause harm? J Am Coll Cardiol. 2015;3(8):654–656.
   Google Scholar
• Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55.
   PubMedGoogle Scholar
• Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52(3):190–199.
   PubMed Web of Science ®Google Scholar
• Jafri SM. The effects of beta blockers on morbidity and mortality in heart failure. Heart Fail Rev. 2004;9(2):115–121.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Fiuzat M, Carson PE, et al. Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PloS One. 2012;7(10):e44324.
   PubMed Web of Science ®Google Scholar
• Liggett SB. Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. Heart Fail Clin. 2010;6(1):27–33.
   PubMedGoogle Scholar
• Smart NA, Kwok N, Holland DJ, et al. Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure. Clin Med Insights Cardiol. 2011;5:55–66.
   PubMedGoogle Scholar
• The BEST investigators. Beta-blocker evaluation of survival trial. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–1667.
   PubMedGoogle Scholar
• Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9(5):354–363.
   PubMed Web of Science ®Google Scholar
• Tepper D. Frontiers in congestive heart failure: effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;5(4):184–185.
   Google Scholar
• CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90(4):1765–1773.
   PubMed Web of Science ®Google Scholar
• Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103(30):11288–11293.
   PubMed Web of Science ®Google Scholar
• Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274(18):12670–12674.
   PubMed Web of Science ®Google Scholar
• Genetically targeted therapy for the prevention of symptomatic atrial fibrillation in patients with heart failure (GENETIC-AF). [cited 2018 Jun 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT01970501
   Google Scholar
• Diez-Manglano J. Economic analysis of the treatment of heart failure with beta-blockers. Med Clin. 2013;141(6):265–270.
   PubMed Web of Science ®Google Scholar
• Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. J Am Coll Cardiol. 2013;61(13):1440–1446.
   PubMed Web of Science ®Google Scholar
• Rohde LE, Bertoldi EG, Goldraich L, et al. Cost-effectiveness of heart failure therapies. Nat Rev Cardiol. 2013;10(6):338–354.
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–2203.
   PubMed Web of Science ®Google Scholar
• Bücher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (organized program to initiate lifesaving treatment in hospitalized patients with heart failure) Registry. J Am Coll Cardiol. 2009;53(2):184–192.
   PubMed Web of Science ®Google Scholar
• Anderson JL, Krause-Steinrauf H, Goldman S, et al. Failure of benefit and early hazard of bucindolol for class IV heart failure. J Card Fail. 2003;9(4):266–277.
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015. p. 103–208.
   Google Scholar
• RedBook Micromedics. [cited 2018 Jun 13]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook
   Google Scholar
• Center for Medicare and Medicaid Services., Physician Fee Schedule. [cited 2018 Jun 13]. Available from: www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/index.html? redirect=/PhysicianFee
   Google Scholar
• Genetic Testing Registry. [cited 2018 Jun 13]. Available from: https://www.ncbi.nlm.nih.gov/gtr/tests/515942/laboratory/
   Google Scholar
• Gohler A, Geisler BP, Manne JM, et al. Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. Value Health. 2009;12(1):185–187.
   PubMed Web of Science ®Google Scholar
• Ziaeian B, Sharma PP, Yu TC, et al. Factors associated with variations in hospital expenditures for acute heart failure in the United States. Am Heart J. 2015;169(2):282–289.
   PubMed Web of Science ®Google Scholar
• Murphy TE, Agostini JV, Van Ness PH, et al. Assessing multiple medication use with probabilities of benefits and harms. J Aging Health. 2008;20(6):694–709.
   PubMed Web of Science ®Google Scholar
• Muthumala A, Drenos F, Elliott PM, et al. Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail. 2008;10(1):3–13.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Ann Sakowski J, Trosman J, et al. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014;16(3):251–257.
   PubMed Web of Science ®Google Scholar
• Fiuzat M, Neely ML, Starr AZ, et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail. 2013;15(3):258–266.
   PubMed Web of Science ®Google Scholar